Approved. Verified the screening directly on the iter-2 branch.

**Integrity (no confabulation signal):**
- 217 decisions for 217 input records — exact match, no missing/duplicate PMIDs
- All entries have decision + pmid + reason fields populated

**Distribution sensible for FMT/rCDI/RCT space:**
- 201 exclude (E1=190 not-RCT dominant; E2=41 not-rCDI; E3=11 no-FMT-arm; E4=3 animal/in-vitro)
- 13 include / 3 uncertain
- 16 candidate primary RCTs to take forward is plausible for this domain (landmark trials: van Nood, Cammarota, Hota, EarlyFMT, Khanna, Allegretti, etc.)

**Reasoning quality (spot-checked):**
- Includes are real rCDI RCTs (EarlyFMT 36152636, 3-arm FMT/bacteriotherapy/vancomycin 33694229, FMT+bezlotoxumab 38501667, FMT vs fidaxomicin 30610862).
- Excludes show genuine criteria application — distinguishes network meta-analyses from primary RCTs (39484168 → E1), CP101 oral microbiome therapeutic from FMT (39366468 → E3), trials where FMT is only an adjunct from FMT-arm trials (39488230 → E3), reviews in IBD (38841848 → E1+E2). Not surface keyword matching.
- Uncertains are genuinely abstract-ambiguous (economic eval alongside RCT, recruitment/design report, n=21 pilot with limited detail) — correctly routed to resolver.

**Operational note (not blocking):** iter-1 timed_out at the 90m claim lease; iter-2 succeeded in ~6 minutes. Reaper correctly expired the stale claim and the re-claim ran clean — agent-lifecycle behaving as designed.

Ready for the resolver to handle the 3 uncertains and downstream extraction.